Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Review Question - QID 103672

In scope icon M 11 E
QID 103672 (Type "103672" in App Search)
A 78-year-old man presents to the emergency room with a three day history of palpitations. He denies dizziness, dyspnea, and chest pain, and says he sleeps comfortably on one pillow each night. His history is significant for diabetes mellitus type 2, hyperlipidemia, and hypertension. Medications include glyburide, lisinopril, and hydrochlorothiazide. The patient has a ten pack-year history of smoking but quit 15 years ago. He does not drink alcohol or use drugs. His heart rate is 115/min and his blood pressure is 145/95 mmHg. Physical examination demonstrates no evidence of heart failure. Electrocardiogram shows atrial fibrillation with rapid ventricular response. Which of the following is an appropriate therapy for this patient:

Metoprolol and aspirin

43%

3/7

Metoprolol and warfarin

43%

3/7

Digoxin and aspirin

14%

1/7

Digoxin and warfarin

0%

0/7

Diltiazem and aspirin

0%

0/7

Select Answer to see Preferred Response

bookmode logo Review TC In New Tab

Medical treatment for atrial fibrillation in stable patients centers around rate control and anticoagulation. This patient's CHADS2 score is 3 (age, hypertension, and diabetes), so in addition to rate control with a non-dihydropyridine calcium channel blocker or beta-blocker, warfarin is indicated for anticoagulation.

The CHADS2 score is a clinical prediction rule for estimating the risk of stroke in patients with atrial fibrillation. The score dictates whether a patient should be treated with aspirin or warfarin anticoagulation therapy. One point is assigned for each of the following: congestive heart failure, blood pressure consistently above 140/90 mmHg, age greater than or equal to 75 years, and diabetes mellitus. Two points are added for prior stroke or TIA or thromboembolism. Patients with a score of zero can safely be treated with aspirin. A score of one indicates moderate risk and either aspirin or warfarin is acceptable. If CHADS2 is two or greater, the patient is high risk for embolic complications and warfarin is indicated.

Guierrez and Blanchard review the diagnosis and treatment of atrial fibrillation and highlight the preference of rate control over rhythm control. The latter is considered if rate control cannot be obtained or if there are persistent symptoms despite adequate rate control. Anticoagulation therapy is needed as an additional measure to lower stroke risk. Warfarin is superior to aspirin or clopidogrel in preventing stroke, despite its narrow therapeutic range and increased risk of bleeding.

Deedwania and Huang explain how dabigatran, a direct thrombin inhibitor, is now approved by the USFDA for stroke prophylaxis in nonvalvular atrial fibrillation. Recent studies have found it to be superior in preventing stroke and systemic embolism and to have a similar bleeding risk when compared with warfarin.

Illustration A is a table of the CHADS2 scoring and the appropriate treatments for each risk category.

Illustration B elucidates the mechanisms of action of some of the anticoagulants.

Incorrect Answers:
Answer 1 and 5: This patient’s CHADS2 score is 3, indicating that warfarin is preferred over aspirin as anticoagulation therapy.
Answer 3 and 4: Digoxin can be used for rate control in atrial fibrillation patients with congestive heart failure, who are intolerant of beta blockers or non-dihydropyrididine calcium channel blockers, though one of the latter two would be the preferred.

ILLUSTRATIONS:
REFERENCES (2)
Authors
Rating
Please Rate Question Quality

5.0

  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon

(2)

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options